IMPACT OF DISPARITIES IN CARDIOVASCULAR CARE ON AFRICAN AMERICAN DEATHS Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry.

Slides:



Advertisements
Similar presentations
Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD.
Advertisements

Context and Overview of Recommended Actions to Reduce Psychiatric Readmissions Michael Trangle, MD Associate Medical Director, Behavioral Health Division.
Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge.
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: /NEJMSA Niteesh K. Choudhry,
Innovative Pharmacy Services Jann B. Skelton, RPh, MBA Vice President of Operations MEDICA.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
The Current Indications for ICD in HF Patients Should be Driven by HF Guidelines Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia,
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
DO DIETITIANS HAVE A ROLE? Renee Wing, Sodexo Dietetic Intern Orange Park Medical Center January 22, 2013.
Population Impact Measures (PIM)
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Medicare Managed Care and Primary Care Quality: Examining Racial/Ethnic Effects across States Jayasree Basu, Ph.D. AHRQ 2009 Annual Conference.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
CARDIOVASCULAR DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Cardiovascular Morbidity Following Modern Treatment for Hodgkin Lymphoma: Age- and Sex- Specific Estimates of Risk in the Doxorubicin Era. D. Hodgson 1,
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Informing Public Policy to Address Health Care Disparities Boisey Barnes, MD, F.A.C.C. Founding Member and Trustee Association of Black Cardiologists.
New Zealand Cardiology Wards and Adventures Taylor Myers Locke.
1 Measuring What Matters: Care Transitions Karen Adams, PhD Senior Program Officer National Quality Forum February 4, 2008.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
The Impact of Racial and Ethnic Disparities in Influenza Vaccination on Minority Deaths Kevin Fiscella, MD, MPH Departments of Family Medicine Community.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
How to Analyze Therapy in the Medical Literature (part 2)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
Using Quality Improvement to Insure Equality in Healthcare Quality Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry Departments.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Elizabeth Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Director, Clinical Research Center Associate Dean of Clinical Research.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Angela Aziz Donnelly April 5, 2016
Findings suggest: Improvement was noted in both BMI and reported physical activity although the differences did not reach statistical difference. Behavior.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Home Health Remote Patient Monitoring For Heart Failure
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Improving Chronic Care Management
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Cardiac Biomarkers.
A. Heart failure: A challenge to the healthcare delivery system
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Challenges and solutions in rural ND
Risk adjustment using administrative and clinical data: model comparison
LRC-CPPT and MRFIT Content Points:
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
Data Needs for a Model Martin O’Flaherty Simon Capewell
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
The Efficacy of the Teach-Back Method of Education on Readmission Rates in Heart Failure Patients Catherine Lynch Abstract Teach-Back Method The teach-back.
Cardiovascular Epidemiology and Epidemiological Modelling
Stroke Prevention: An Evidence-Based Update
Presentation transcript:

IMPACT OF DISPARITIES IN CARDIOVASCULAR CARE ON AFRICAN AMERICAN DEATHS Kevin Fiscella, MD, MPH University of Rochester School of Medicine & Dentistry

Background  Burgeoning health care disparities literature  Challenge of prioritizing health care disparities  Need for a common metric for evaluation

Purpose  Population impact - annual deaths  Present a simple model using black- white disparities in CVD  Estimate the number of African American CVD deaths that would be avoided/delayed if disparities in CVD care were eliminated

The Model AA deaths prevented/delayed = absolute disparity x absolute risk reduction

Components of absolute disparity (AD)  Disparity in provision/prescription of intervention  Disparities in use of or adherence to intervention

Estimating AD AD= (EP B x Rx w x Ad w ) - (EP B x Rx B x Ad B ) EP B = Eligible black population i.e. the number who are candidates for the intervention annually Rx w = Provision/prescription of the intervention for whites Ad w = Adherence to the intervention for whites Rx B = Provision/prescription of the intervention for blacks Ad B = Adherence to the intervention for blacks

Common thread: clinician-patient communication  Communication affects patients’ willingness to accept a treatment and clinician’s willingness to provide or prescribe it  Communication affects patients’ adherence

Absolute risk reduction  Baseline mortality in the absence of intervention  Relative risk reduction associated with the intervention  ARR= RRR x base mortality rate

CVD Interventions AMI following hosp discharge – drug treatment AMI – reperfusion and revascularization Chronic angina - drug treatment Chronic heart failure - drug treatment Heart failure following hosp discharge – drug treatment Hyperlipidemia – drug treatment Hypertension - drug treatment Long-term post MI – drug treatment Unstable angina –drug treatment Unstable angina - drug treatment Sudden death prevention – ICD insertion

Population size and mortality rates ConditionSize of population (crude) Base annual Mortality (crude) AMI admits83,49022% HF admits110,00033% UA admits 54,00016% Chronic AMI950,0005% Chronic angina575,002.5% Chronic HF444,00010% Hypertension9.4 million1.6% Hyperipidemia10.4 million0.5% Sudden death13,60015%

Key disparity (black/white ratio) estimates  Drug treatment in the year following hospital discharge ( )  CABG ( )  PTCA ( )  Fibrinolysis ( )  Adherence to treatment for chronic condition – 0.80 ( )

Adjusting summed deaths  Avoiding double counting from hospital readmissions from same year and transfers  Avoiding double counting from comoribidity e.g. AMI and HF, CAD and hypertension  Adjusting for less than additive relative risk

Findings ConditionDisparity Deaths AMI first year following admission1,200 Chronic angina450 Heart failure (> 1 year following admission)1,750 Heart failure first year following admission1,930 Hyperlipidemia430 Hypertension1420 AMI (>1 year following admission)930 Sudden death prevention- ICD200 Unstable angina first year following admission800 TOTAL8,800

Key findings  Common conditions with high mortality requiring daily adherence have the greatest impact on disparities e.g. heart failure and AMI.  Interventions with high reach e.g. cardiac rehabilitation (990) have greater impact than those with smaller reach e.g. reperfusion therapy (740) or ICDs (200).  Disparities in drug adherence is a major driver accounting for 4,980 deaths.

Limitations  Lack of reliable data for many estimates  Assumptions e.g. differential impact, sustained benefit, synergistic effects  No stratification by age or gender  Annual deaths not QALYS

Conclusions  Population impact represents a key (though not the only) metric for prioritizing health care disparities  The population impact model could be adapted by health care organizations that care for defined populations using their own internal data to assess the impact of health care disparities

Acknowledgements Funding: RWJF and NHLBI/NIH Collaborators: Richard Dressler Advice: Simon Capewell

Sensitivity  95% CI - 5,700-11,110  Adherence disparity: , ,290